Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference
MWN-AI** Summary
Kuros Biosciences, a leader in innovative biologic technologies, is set to present at the Piper Sandler 37th Annual Healthcare Conference from December 2–4, 2025, at The Lotte New York Palace in New York City. The presentation, led by CEO Chris Fair on December 3, will spotlight the company's ongoing commercial momentum and significant advancements in its MagnetOs portfolio, a groundbreaking advanced bone graft technology.
Kuros is committed to transforming its business model to achieve sustainable profitability and operational efficiency. With recent investments in operational infrastructure, the company aims to enhance its long-term growth potential and expand its presence in global markets and new clinical indications.
The MagnetOs technology, which has shown remarkable success in clinical studies, boasts nearly double the fusion rate compared to traditional autografts in posterolateral fusions (PLFs), with published results indicating a 79% fusion success rate for MagnetOs versus 47% for autografts. The product utilizes NeedleGrip™, a proprietary submicron surface technology, stimulating bone growth by leveraging the immune system without the need for added cells or growth factors. This ready-to-use solution is moldable, reliable, and FDA-cleared for use throughout the spine, presenting a safe alternative free from risks associated with tissue-related disease transmission.
In essence, Kuros Biosciences is not just advancing its product portfolio but also positioning itself for robust future performance through strategic enhancements in commercial operations and clinical breakthroughs. Stakeholders can follow the live webcast of the presentation for insights into the company's promising trajectory. For further information, please visit the Kuros website at kurosbio.com and the Piper Sandler conference website.
MWN-AI** Analysis
As Kuros Biosciences prepares to present at the Piper Sandler 37th Annual Healthcare Conference, investors should closely analyze the company’s strategic focus on its MagnetOs portfolio, which is making strides in innovative bone graft technologies. The potential for sustained commercial momentum is buoyed by promising clinical advancements, as evidenced by the near-doubling of fusion rates in recent studies against traditional autografts.
A key highlight of the presentation will likely revolve around Kuros’s strategic pivot towards a business model fortified by recent operational investments aimed at achieving profitability and increasing operational leverage. Such transformations can positively influence cost management and enhance margins, giving Kuros a competitive edge in the burgeoning biologics market.
In terms of market opportunities, Kuros’s expansion into additional indications and international markets is significant. With the growing global demand for innovative medical solutions, particularly in orthopedics and spinal surgeries, Kuros stands to benefit from its first-mover advantage with MagnetOs. This product's FDA clearance for various spinal applications and the absence of risk related to tissue transmission resonate strongly in a conservative medical landscape where patient safety is paramount.
From an investment perspective, Kuros may represent a compelling opportunity within the healthcare sector, particularly as the presentation outlines a clear pathway to revenue growth and market penetration. Moreover, the robust clinical data backing MagnetOs could attract interest from both analysts and potential corporate partners, providing a platform for future collaborations and financial upside.
Investors should monitor developments from the conference, particularly regarding Kuros’s operational strategies and market positioning, as these will be critical in assessing the company’s trajectory in the months ahead.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Kuros Biosciences to present at the Piper Sandler 37 th Annual Healthcare Conference
Schlieren (Zürich), Switzerland, November 26, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, will present at the Piper Sandler 37th Annual Healthcare Conference, taking place December 2–4, 2025 at The Lotte New York Palace in New York City.
The Company’s presentation will highlight continued commercial momentum, clinical advancement across the MagnetOs portfolio, and ongoing expansion in new indications and the global market. Kuros will also provide insights into its path to sustainable profitability and operational leverage through the transformation of its business model, supported by recent investments in operational infrastructure designed to secure long-term growth.
A live webcast of the presentation will be available on the Piper Sandler conference website for 30 days following the event: https://statusproconf.com/Agenda/event/2091
Presentation Details
Event : Piper Sandler 37th Annual Healthcare Conference
Presenter : Chris Fair, CEO, Kuros Biosciences
Format : Company Presentation
Date : Wednesday, December 3, 2025
Location : The Lotte New York Palace, New York, NY
For more information about the conference, please visit Piper Sandler’s website at: https://www.pipersandler.com/
For further information, please contact:
| Alexandre Müller | Daniel Geiger |
| Investor Relations | Chief Financial Officer |
| Tel +41 43 268 32 31 | Tel +41 44 733 47 41 |
| IR@kurosbio.com | daniel.geiger@kurosbio.com |
About MagnetOs
Growing bone with MagnetOs TM gives surgeons confidence where it matters most – delivering predictable fusion outcomes. 1 In a Level I human clinical study published in Spine, MagnetOs achieved nearly twice the fusion rate of autograft (79% vs. 47%) in posterolateral fusions (PLFs). 1 Among active smokers – who made up 1 in 5 patients – the fusion difference between MagnetOs and autograft was even more dramatic .* † 1, 2 MagnetOs grows bone on its own thanks to NeedleGrip TM – a proprietary submicron surface technology that harnesses the immune system to stimulate bone growth, without added cells or growth factors. § ‡ 4- 6 Ready-to-use, easy to mold, and reliably staying put, MagnetOs carries no intrinsic risk of human tissue-related disease transmission and is FDA cleared for use throughout the spine, including interbody procedures. ¶ 7 -12
Indications Statement
Please refer to the instructions for use for your local region for a full list of indications, contraindications, warnings, and precautions.
About Kuros Biosciences
Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company’s first commercial product, MagnetOs TM , is a unique advanced bone graft that has already been used across five continents. For more information on the company, its products and pipeline, visit kurosbio.com .
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.
* 19 of initial 100 patients were active smokers.
† Radiographic fusion data of the smoker subgroup were not statistically analyzed as a subgroup and were not included in the peer-reviewed publication of the study.
‡ Results from in vitro or in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit kurosbio.com.
§ MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft.
¶ MagnetOs must also be used with an intervertebral body fusion device cleared by FDA for use with a bone void filler. MagnetOs Flex Matrix must be hydrated with BMA & mixed with autograft in posterolateral spine & intervertebral disc space. MagnetOs Granules must be hydrated with blood in the intervertebral disc space.
- Stempels, et al. Spine . 2024;49(19):1323-1331.
- Van Dijk, LA. 24th SGS Annual Meeting (Swiss Society of Spinal Surgery). Basel, Switzerland. Aug 2024.
- Data on file. MagnetOs Putty and MagnetOs Easypack Putty.
- Van Dijk, et al. eCM . 2021;41:756-73.
- Van Dijk, et al. J Immunol Regen Med . 2023;19:100070.
- Duan, et al. eCM . 2019; 37:60-73.
- Instructions for Use (IFU) MagnetOs Granules.
- Instructions for Use (IFU) MagnetOs Putty.
- Instructions for Use (IFU) MagnetOs Easypack Putty.
- Instructions for Use (IFU) MagnetOs Flex Matrix.
- Instructions for Use (IFU) MagnetOs MIS.
- Data on file. MagnetOs Putty and MagnetOs Easypack Putty
Attachment
FAQ**
How does Kuros Biosciences Ltd CSBTF plan to leverage the successful clinical data from the MagnetOs portfolio to expand into new indications and global markets?
Can you share insights on the operational infrastructure investments that Kuros Biosciences Ltd CSBTF has made to achieve sustainable profitability and enhance business model transformation?
Given the impressive fusion rates observed with MagnetOs, what strategies does Kuros Biosciences Ltd CSBTF have in place to educate and engage surgeons and healthcare professionals in adopting this technology?
What are the anticipated milestones for the MagnetOs portfolio, and how does Kuros Biosciences Ltd CSBTF plan to communicate these developments to investors and stakeholders moving forward?
**MWN-AI FAQ is based on asking OpenAI questions about Kuros Biosciences Ltd (OTC: CSBTF).
NASDAQ: CSBTF
CSBTF Trading
0.0% G/L:
$32 Last:
250 Volume:
$32 Open:
